TetraLogic Pharmaceuticals, Malvern, says it's raised $6 million in new investment funds from Nextech Invest Ltd., Zurich, Switzerland, bringing total fundraising for the past 12 months to $43 million. TetraLogic says the money will pay for completed "Phase 2a" clinical studies for TL32711, "a small-molecule peptidomimetic" that makes it easier to target and kill cancer cells.

TetraLogic employs around 20 professionals; the company says more than 100 researchers are working on trials of its drugs at the University of Pennsylvania (Abramson Cancer Center), the Fox Chase Cancer Center, and Wistar Institute, all in Philadelphia, among other research centers.

"TetraLogic is a great fit for our oncology portfolio," Matyas Vegh, Nextech managing partner, said in a statement. "We look forward to working with TetraLogic's management and investors to build TL32711 into a leading cancer therapeutic."